1.Moellering, RC Jr. Vancomycin-resistant enterococci. Clin Infect Dis 1998; 26:1196–1199.
2.Johnson, AP. The pathogenicity of enterococci. J Antimicrob Chemother 1994; 33:1083–1089.
3.Maki, DG, Agger, WA. Enterococcal bacteremia: clinical features, the risk of endocarditis, and management. Medicine (Baltimore) 1988; 67:248–269.
4.Murray, BE. The life and times of the enterococcus. Clin Microbiol Rev 1990; 3:46–65.
5.Weinstein, MP, Towns, ML, Quartey, SM, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24:584–602.
6.National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990 to May 1999, issued June 1999. Am J Infect Control 1999; 27:520–532.
7.Edmond, MB, Wallace, SE, McClish, DK, et al. Nosocomial bloodstream infections in United States hospitals: a three year analysis. Clin Infect Dis 1999; 29:239–244.
8.Noskin, GA, Till, M, Patterson, BK, Clarke, JT, Warren, JR. High-level gentamicin resistance in Enterococcus faecalis bacteremia. J Infect Dis 1991;164:1212–1215.
9.Gray, J, Marsh, PJ, Stewart, D, Pedler, SJ. Enterococcal bacteremia: a prospective study of 125 episodes. J Hosp Infect 1994; 27:179–186.
10.Patterson, JE, Sweeney, AH, Simms, M, et al. An analysis of 110 serious enterococcal infections. Epidemiology, antibiotic susceptibility, and outcome. Medicine (Baltimore) 1995; 74:191–200.
11.Noskin, GA, Peterson, LR, Warren, JR. Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome. Clin Infect Dis 1995; 20:296–301.
12.Vergis, EN, Hayden, MK, Chow, JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Ann Intern Med 2001; 135:484–492.
13.Bone, RC, Balk, RA, Cerra, FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644–1655.
14.Knaus, WA, Draper, EA, Wagner, DP, Zimmerman, JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818–829.
15.Facklam, RR, Collins, MD. Identification of enterococcus species isolated from human infections by a conventional test scheme. J Clin Microbiol 1989; 27:731–734.
16.National Committee for Clinical Laboratory Standards. Methods for Dilution Antimocrobial Susceptibility Testing for Bacteria that Grow Aerobically, ed. 6. Villanova, Pa: National Committee for Clinical Laboratory Standards; 2004, NCCLS document M7-A6.
17.Reid, KC, Franklin, RC, Patel, R. Clinical and epidemiological features of Enterococcus casseliflavus/flavescens and Enterococcus gallinarum bacteremia: a report of 20 cases. Clin Infect Dis 2001; 32:1540–1546.
18.Choi, SH, Lee, SO, Kim, TH, et al. Clinical features and outcomes of bacteremia caused by Enterococcus casseliflavus, and Enterococcus gallinarum: analysis of 56 cases. Clin Infect Dis 2004; 38:53–61.
19.Toye, B, Shymanski, J, Bobrowska, M, et al. Clinical and epidemiologic significance of enterococci intrinsically resistant to vancomycin (possessing the vanC genotype). J Clin Microbiol 1997; 35:3166–3170.
20.Leclercq, R, Dutka-Malen, S, Duval, J, et al. Vancomycin resistance gene vanC is specific to Enterococcus gallinarum. Antimicrob Agents Chemother 1992; 36:2005–2008.
21.Patel, R, Uhl, JR, Kohner, P, et al. Multiplex PCR detection of vanA, vanB, vanC-1, and van C-2/3 genes in enterococci. J Clin Microbiol 1997; 35: 703–707.
22.Garner, JS, Jarvis, WR, Emori, TG, Horan, TC, Hughes, JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128–140.